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Background. Chronic opioid exposure, as a treatment for a variety of disorders or as drug of misuse, is common world-
wide, but behavioural and brain abnormalities remain under-investigated. Only a small percentage of patients who re-
ceive methadone maintenance treatment (MMT) for previous heroin misuse eventually achieve abstinence and studies on
such patients are rare.
Method. The Cambridge Neuropsychological Test Automated Battery and T1 weighted magnetic resonance imaging
(MRI) were used to study a cohort of 122 male individuals: a clinically stable opioid-dependent patient group receiving
MMT (n = 48), an abstinent previously MMT maintained group (ABS) (n = 24) and healthy controls (n = 50).
Results. Stable MMT participants deliberated longer and placed higher bets earlier in the Cambridge Gambling Task
(CGT) and showed impaired strategic planning compared with healthy controls. In contrast, ABS participants showed
impairment in choosing the least likely outcome, delay aversion and risk adjustment on the CGT, and exhibited non-
planning impulsivity compared with controls. MMT patients had widespread grey matter reductions in the orbitomedial
prefrontal cortex, caudate, putamen and globus pallidus. In contrast, ABS participants showed midbrain–thalamic grey
matter reductions. A higher methadone dose at the time of scanning was associated with a smaller globus pallidus in the
MMT group.
Conclusions. Our ﬁndings support an interpretation of heightened impulsivity in patients receiving MMT. Widespread
structural brain abnormalities in the MMT group and reduced brain structural abnormality with abstinence suggest
beneﬁt of cessation of methadone intake. We suggest that a longitudinal study is required to determine whether abstin-
ence improves abnormalities, or patients who achieve abstinence have reduced abnormalities before methadone
cessation.
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Introduction
Worldwide, long-term exposure to opioids such as mor-
phine, codeine, heroin and methadone is common, both
in the substance misuse and other clinical populations.
Chronic use of opioids leads to long-lasting changes, in-
cluding tolerance, sensitization and physical depend-
ence (Trujillo, 2002). One of the most common opioid
drugs to be misused is heroin, which is also prescribed
in the UK as ‘diamorphine’ as an analgesic (Strang et al.
2012). For those seeking treatment after developing
dependence following repeated exposure to illicit her-
oin, methadone maintenance treatment (MMT) is the
most commonly offered therapeutic intervention. In
Scotland alone, 30 000 patients receive MMT as part of
a ‘harm reduction programme’ to reduce or cease heroin
use, diminish associated criminality, and reduce the risk
of blood-borne virus infection (McKeganey et al. 2006).
However, an MMT programme is associated with low
rates of sustained abstinence with as few as 17–28% of
those dependent on MMT achieving abstinence (The
Scottish Government, 2010). One of the core features
of opioid dependence is the dysregulation of dopamin-
ergic neurotransmission, including decreased dopamine
receptor availability and release (Gradin et al. 2014),
associated with functional impairments in frontal
brain regions innervated by dopamine. However, it is
not known whether the effects of opioids could lead
mechanistically to long-lasting changes, or could be re-
versible following a period of abstinence (Ersche et al.
2005; Baldacchino et al. 2015).
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Chronic misuse of drugs appears to be associated
with a variety of cognitive abnormalities. Such deﬁcits
may have important clinical consequences: e.g. increas-
ing drug-seeking, presumably due to a failure of im-
pulse control and impaired engagement in therapeutic
programmes, with increased rates of relapse following
treatment (Rogers & Robbins, 2001). In comparison
with work on stimulants and cannabis, there has been
less research on cognitive impairments associated with
opioid dependence (Baldacchino et al. 2012). Opioid-
dependent subjects discounted the value of delayed
money rewards more than non-drug-using participants,
and discounted the value of delayed heroin more than
delayed money (Madden et al. 1997). Whilst some
researchers concluded that opioid misuse is not asso-
ciated with frontal lobe impairments, others reported
that it is associated with a broad range of deﬁcits such
as attentional control, planning and spatial working
memory (Ornstein et al. 2000). More recently, ‘reﬂection
impulsivity’, the extent to which subjects sample infor-
mation before responding, has been reported as
decreased in currently opioid-dependent and former
substance misusers (Clark et al. 2006). A variety of cog-
nitive deﬁcits associated with opioid misuse has, there-
fore, been reported, ranging from general deﬁcits, to
selective memory impairment, increased discounting
and impulsivity, to no prefrontal-linked cognitive
impairments. Importantly, these studies have revealed
signiﬁcant overlaps in candidate markers of impulsivity
(Dalley et al. 2011; Robbins et al. 2012).
A post-mortem study reported an increased preva-
lence of ischaemic brain lesions in the globus
pallidus in opioid-dependent individuals (Andersen &
Skullerud, 1999). Structural magnetic resonance imaging
(MRI) studies of human opioid-dependent populations
have revealed signiﬁcant grey matter reductions in the
prefrontal and temporal cortices (Lyoo et al. 2006; Liu
et al. 2009; Yuan et al. 2009) and increased white matter
hyper-intensities, mainly in frontal areas (Lyoo et al.
2004). Indeed, overall results show that the neuroana-
tomical impairments are located in neural networks
linked to executive and attentional function, such as
the dorsolateral prefrontal cortex, anterior cingulate cor-
tex and medio-temporal cortices. Abstinent previously
heroin-dependent individuals have shown, after 3 days
of abstinence, signiﬁcant grey matter reductions in the
left frontal gyrus and cingulate gyrus. However, after 1
month of abstinence there were no signiﬁcant differences
between patients and controls in any structural brain re-
gion (Wang et al. 2011).
Previous studies investigating the chronic effects of
opioid use either due to heroin misuse or as part of
MTT have largely focused on the evaluation of cogni-
tive impulsivity and non-planning impulsivity using
Barratt’s Impulsivity Scale (Patton et al. 1995; Ersche
et al. 2005; Baldacchino et al. 2015). The prefrontal cor-
tex may play a key role in processing such information
(Rogers et al. 1999). However, to our knowledge, only
one study has reported signiﬁcant orbitofrontal struc-
tural abnormalities associated with heroin and metha-
done use (Ersche et al. 2006).
The aim of this study was to test the following
hypotheses:
(i) Behavioural impairment in cognitive impulsivity
and non-planning impulsivity are related to differ-
ent stages of treatment (stable MMT use v.
abstinent).
(ii) Stable MMT patients exhibit more reductions in
grey matter volume in a priori regions of interest,
such as the prefrontal cortex and basal ganglia, be-
cause these regions have been linked to impulsivity
and reported as abnormal in structure in opioid mis-
use (Robbins et al. 2012), relative to controls and ab-
stinent patients. MMT patients may be most
vulnerable to the effects of current opioid exposure
associated with cognitive impulsivity and non-
planning impulsivity (Robbins et al. 2012). We there-
fore predicted that behavioural measures of impul-
sivity correlate with brain structure measures.
Method
Participants
Study approval was granted by the East of Scotland, the
Lothian and Glasgow Research Ethics Committees and
written informed consent obtained from all participants.
National Health Service (NHS) Scotland Research
Governance approvals were provided by the NHS
Fife Research and Development Department. The
University of Dundee was the sponsor for this study.
A total of 122 male individuals were enrolled in the
study. They underwent detailed clinical screening
assessed by a clinician (A.B. or S.G.) that included
the collection of sociodemographic information, and
semi-structured interviews to ascertain detailed histor-
ies of drug and alcohol use and opioid-dependence sta-
tus (Marsden et al. 1998). Mental health status and
history were assessed using the Mini International
Neuropsychiatric Interview (MINI Plus, version 5.0;
Sheehan et al. 1998). Current and pre-morbid intelligence
was estimated using the Wechsler Abbreviated Scale of
Intelligence and National Adult Reading Test (NART)
(Nelson & Willison, 1991; Woerner & Overstreet, 1999).
The Fagerström Test for Nicotine Dependence
(Fagerstrom & Schneider, 1989) was also used.
Case records from the addiction, psychiatric and
general practitioners’ services helped in the identiﬁca-
tion of overdose episodes, conﬁrmed the absence of a
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history of epilepsy and other neurological phenomena,
hepatitis B, C and HIV status and diagnoses of person-
ality disorders (e.g. borderline). These records also
allowed us to validate medical and psychiatric histor-
ies, substance misuse career timelines and quantify
current drug and alcohol use. Exclusion criteria were
past or current histories of psychotic disorder, post-
traumatic stress disorder, neurological and neurodeve-
lopmental disorders, head injury, conﬁrmed history of
non-fatal overdose episodes and co-occurring benzodi-
azepine, stimulant and alcohol dependence, and anti-
social and borderline personality disorder.
The methadone group (n = 48) had a diagnosis of
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition (DSM-IV) opioid dependence and were
engaged in a methadone maintenance programme
(MMT) with objective conﬁrmation of the absence of il-
licit drug use for more than 6 months. The previously
dependent opioid (abstinent; ABS) group (n = 24) had
a history of chronic opioid use with an abstinence dur-
ation exceeding 6 weeks. As patients were either stably
maintained on methadone or were stably abstinent, no
acute intoxication or withdrawal effects were observed.
A representative subset of these volunteers took part in
stages 2 and 3. Both MMT and ABS groups had been
taking between 30 and 120 mg of methadone daily on
an MMT programme and presented with more than 3
years of continuous daily illicit heroin use. The two
groups were matched by lifetime drug use and metha-
done doses [initial titration of methadone dose
(ITMD), current methadone treatment dose (CMTD)
and/or last stable methadone dose (LSMD)]. The
ITMD included the initial titration dose of methadone
that each patient received, deﬁned as the dose of metha-
done required to reduce heroin withdrawal symptoms
at the commencement of MMT and was between 10
and 30 mg daily, depending on objective evidence of
opioid withdrawal symptoms. Ongoing abstinence
from illicit drug use was conﬁrmed just prior to both
neuropsychological testing, and scanning, using an
onsite multidrug urine test (Armbruster & Krolak,
1992). Some participants withdrew from scanning and
from neuropsychological assessment because they
were not contactable or they were not able to take
part. Details of participants included in the analysis
are presented in Table 1. Fig. 1 describes the cohorts
who participated in the stages of the study as described
below.
Stage 1 – behavioural outcomes
Each participant was assessed using the standardized
Cambridge Neuropsychological Test Automated
Battery (CANTAB; http://www.cambridgecognition.
com). Executive functions were assessed using the
Cambridge Gambling Task (CGT) and Stockings of
Cambridge (SOC) tests. These tasks assessed cognitive
impulsivity and non-planning impulsivity, respective-
ly (Patton et al. 1995; Ersche et al. 2005; Baldacchino
et al. 2015).
Statistical analysis of the behavioural outcomes
Data meeting assumptions of normality and homogen-
eity of variance were analysed using analysis of variance
(ANOVA) and analysis of covariance (ANCOVA). All
other data were compared using appropriate non-
parametric tests (e.g. Kruskal–Wallis and Mann–
Whitney tests). ANOVA was used to test for group dif-
ferences. To control for family-wise error, we used post-
hoc Bonferroni-corrected pairwise comparisons. After
correction, results with p < 0.05 were considered signiﬁ-
cant. ANOVA was used to test for group differences.
Effect sizes were calculated as Cohen’s d statistics and
analyses conducted using SPSS v. 20 (SPSS Inc., USA).
Stage 2 – neuroimaging
Scanning
Data were acquired with a Siemens 3 T Tim Trio at the
Clinical Research Centre, Ninewells Hospital and
Medical School, Dundee, UK. ‘Structural’ T1 weighted
images were acquired with a voxel size 0.8 × 0.8 × 1.0
mm3 with whole brain coverage, repetition time (TR)
= 1.9 s and echo time (TE) = 2.64 ms and reported by a
consultant radiologist for incidental ﬁndings.
Image analyses
Voxel-based morphometry was done using SPM8
(http://www.ﬁl.ion.ucl.ac.uk/spm/). For pre-
processing, T1 weighted images for each participant
were segmented into grey and white matter probabil-
ity maps, spatially normalized with modulation to pre-
serve the total amount of grey matter and smoothed
with an 8 mm Gaussian kernel (Ashburner & Friston,
2005). We used t tests to test the null hypothesis of
no difference between MMT patients and controls.
The threshold of signiﬁcance was deﬁned as p < 0.05
at a whole-brain corrected level using a customized
version of a popular Monte Carlo technique (Slotnick
et al. 2003) (http://www2.bc.edu/~slotnics/scripts.htm).
Brain regions were identiﬁed by converting Montreal
Neurological Institute coordinates into Talairach coor-
dinates using the Yale conversion calculation (http://
bioimagesuite.yale.edu/mni2tal/index.aspx) and in-
spection of the Talairach Atlas (Talairach &
Tournoux, 1988).
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Table 1. Demographic and clinical characteristics
Stage 1 Stage 2 Stage 3
MMT ABS HC Signiﬁcance MMT ABS HC Signiﬁcance MMT ABS HC Signiﬁcance
n 48 25 50 33 15 23 18 15 23
Age, years 30.2 (4.7) 36.6 (3.9) 28.0 (7.0) ABS >MMT* 33.9 (4.2) 37.0 (3.7) 30.8 (6.9) N.S. 33.6 (4.8) 37.0 (3.7) 30.8 (6.9) N.S.
NART 103.0 (9.4) 111.3 (2.1) 117.9 (6.0) MMT <HC*** 114.6 (5.2) 109.7 (7.9) 117.0 (7.0) ABS <HC* 113.0 (4.8) 109.7 (7.9) 117.0 (7.0) ABS <HC*
ITMD, mg/day 50.0 (19.0) 49.8 (19.0) N.S.
SMD, mg/day 66.6 (21.5) 79.0 (36.0) – N.S. 74.7 (18.8) 79.0 (36.0) – N.S. 71.1 (21.2 79.0 (36.0) – N.S.
Age of ﬁrst use of
heroin, years
19.1 (3.7) 19.1 (5.7) – N.S. 16.1 (3.5) 14.1 (3.6) – N.S. 16.1 (3.5) 14.1 (3.6) – N.S.
Duration of opioid use,
years
9.2 (19.6) 3.8 (11.2) – N.S. 9.1 (19.6) 3.8 (11.2) – N.S. 6.2 (21.6) 3.8 (11.2) – N.S.
Age of ﬁrst injecting
opioids, years
18.1 (8.0) 22.3 (7.0) – N.S. 18.1 (8.0) 22.3 (7.0) – N.S. 18.1 (8.0) 22.3 (7.0) – N.S.
Fagerström total score 5.16 (6.4) 9.2 (14.1) – N.S. 3.8 (1.9) 8.1 (13.0) – N.S. 3.6 (1.9) 8.1 (13.0) – N.S.
Duration of abstinence,
days
– – – – – 160.6 (66.7) – – – 155.4 (68.7) – N.S.
Data are given as mean (standard deviation).
MMT, Methadone maintenance group; ABS, abstinent group; HC, healthy control group; N.S., not signiﬁcant; NART, National Adult Reading Test; ITMD, initial methadone titration
dose; SMD, stable methadone dose.
* p < 0.05, *** p < 0.001.
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Stage 3 – behaviour and neuroimaging and
correlations with opioid exposure
Correlation analyses were similarly used to test null
hypotheses of no relationship between grey matter in-
dices and measures of opioid exposure: ITMD and
CMTD. Correlation analyses were also used to test
null hypotheses of no relationship between grey matter
abnormalities and CGT or SOC behavioural measures.
Statistical analysis for treatment outcome
An exploratory analysis to investigate potential predic-
tors of outcome was also done. Logistic regression with
6-fold cross-validation was used to generate an un-
biased prediction of treatment outcome (MMT v.
ABS) in the experimental groups using the following
predictors: frequency use, withdrawal exposure and
treatment. We were interested in particular in two
measures: (1) ITMD and (2) stable methadone dose
(SMD) for the MMT group and the LSMD for the
ABS group. Analyses were conducted using SPSS for
Windows v. 20 (SPSS Inc., USA).
Results
Participants
MMT and ABS groups were matched for clinical char-
acteristics: SMD, age of ﬁrst use of heroin, years of opi-
oid use, age of ﬁrst injecting opioids and Fagerström
total score in the ﬁrst stage of the study. The ABS
group were on average older than the MMT group
(p < 0.05) and the MMT group had lower intelligence
quotient scores than the healthy control group (p <
0.001). In the second and third stages, the ABS group
differed signiﬁcantly in NART scores from the healthy
control group (p < 0.05) but the clinical characteristics
remained matched (p > 0.05). Table 1 shows the demo-
graphic and the substance use data of the participants.
Behavioural results
Signiﬁcant decision-making abnormalities for the
MMT and ABS groups relative to the control group
were identiﬁed for cognitive impulsivity (CGT) (p <
0.01) and non-planning impulsivity (SOC) (p < 0.01)
as summarized in Table 2.
Neuroimaging results
As shown in Fig. 2, signiﬁcant reductions in grey mat-
ter probability were present in the MMT group relative
to controls: medial-orbital (18, 54, 0) cortices, bilateral
caudate (18, 12, 12; −18, 12, 12), bilateral globus palli-
dus (10, 10, 2; −10, 10, 2), nucleus accumbens (−6, 10,
10), anterior cingulate (−1, 34, 16) and bilateral insula
(34, −6, 16; −38, −4, −0). Signiﬁcant reductions in
grey matter were present in the ABS group relative
to controls: thalamus (−2, −6, 10) and midbrain (2,
30, 36). This is summarized in Table 3. In the prefrontal
cortex, the region of interest was centred on −2, 34, 18.
Fig. 1. Flowchart of study stages and participants. MMT, Methadone maintenance treatment group; ABS, abstinent group;
HC, healthy controls.
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The MMT group had signiﬁcantly reduced grey matter
probability (p < 0.001) in comparison with controls.
Fig. 3 shows that current SMD for the MMT group
correlated negatively with bilateral globus pallidus,
grey matter probability (20, 2, 6; −20, 4, 6). Increased
CGT risk adjustment was associated in the MMT
group with bilateral globus pallidus grey matter reduc-
tions (20, −4, 6; −24, −6, 10) and increased CGT risk
taking was associated with signiﬁcantly decreased
grey matter in the orbitofrontal and inferior medial
prefrontal cortices (10, 62, 8; 10, 48, −20) in the MMT
group. Increased mean subsequent moves in the SOC
were correlated with grey matter reductions in the ros-
tromedial prefrontal cortex (10, 26, −16) in MMT
patients, which also correlated with longer times to
solve complex problems (such as ‘5-moves’).
In Fig. 4 the LSMD for the ABS group correlated
negatively with bilateral: bed nucleus of stria termina-
lis (BNST) (20, 18, −14; −14, 18, −14), midbrain (−2,
−22, 14) and thalamus (−6, −18, 0) grey matter prob-
ability. Greater delay aversion on the CGT in the
ABS group was associated with periaqueductal grey
matter reductions (8, −26, 2). Increased mean subse-
quent moves of the SOC correlated negatively with
grey matter probability in the putamen (−28, 16, 2)
and bilateral BNST (24, 18, −24; −22, 16, −24) in
ABS patients.
Summary of the neuroimaging and behavioural
results
Regions of grey matter reduction in the MMT and ABS
participants where the variance in grey matter prob-
ability was signiﬁcantly explained by SMD and
LSMD and CGT and SOC behavioural measures are
summarized in Table 4 and Fig. 5.
Predictions of treatment outcome
Using logistic regression with cross-validation (within
study replication), SMD and LSMD predicted treat-
ment status at the time of the present study (being
on MMT treatment v. abstinence) with 92% accuracy
(98% sensitivity and 72% speciﬁcity). In addition,
ITMD, which reﬂected extent of heroin use prior to
commencing MMT, predicted treatment status at the
time of the present study with 86.2% accuracy (85.7%
sensitivity and 86.2% speciﬁcity). This indicates that
in both ITMD, when commencing MMT, and SMD or
LSMD were signiﬁcant predictors for much later treat-
ment outcomes (Table 5).
Discussion
This study tested the hypotheses that both behavioural
and structural grey matter changes were related to
Table 2. Between-group comparisons of the neuropsychological domains
Cognitive test MMT (n = 48) ABS (n = 25) HC (n = 50) Signiﬁcance Effect size Worse
Cognitive impulsivity
(CGT)
Quality of decision
making
0.90 (0.08) 0.85 (0.13) 0.95 (0.05) ABS <HC***,
ABS <MMT***
0.124 ; MMT; ABS
Deliberation time, ms 3247.6 (1520.7) 2936.2 (822.9) 2345.1 (900.0) MMT >HC** 0.062 ; MMT
Risk taking 0.6 (0.02) 0.6 (0.03) 0.6 (0.02) N.S. 0.03
Overall proportion of bet 0.60 (0.12) 0.55 (0.10) 0.58 (0.10) N.S. 0.04
Delay aversion 0.28 (0.17) 0.34 (0.10) 0.23 (0.13) ABS >HC** 0.07 ; ABS
Risk adjustment 0.91 (0.75) 0.79 (0.83) 1.50 (0.84) MMT <HC**,
ABS <HC***
0.06 ; MMT; ABS
Non-planning impulsivity (SOC)
Problems solved in
minimum moves
8.4 (1.8) 7.8 (1.5) 9.2 (1.8) MMT <HC**,
ABS <HC**
0.095 ; MMT; ABS
Problems solved in ﬁve
moves
2.0 (0.2) 1.8 (0.2) 2.7 (0.2) MMT <HC**,
ABS <HC**
0.12 ; MMT; ABS
Mean initial thinking
time ﬁve moves
6.8 (0.2) 7.1 (0.3) 6.2 (0.2) MMT <HC**,
ABS <HC**
0.088 ; MMT; ABS
Mean subsequent
thinking time ﬁve moves
1475.0 (334.6) 1735.8 (413.4) 441.5 (340.5) MMT <HC**,
ABS <HC**
0.09 ; MMT; ABS
Data are given as mean (standard deviation).
MMT, Methadone maintenance group; ABS, abstinent group; HC, healthy control group; CGT, Cambridge Gambling Task;
;, worse; N.S., not signiﬁcant; SOC, Stockings of Cambridge.
** p < 0.01, *** p < 0.001.
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different stages of the treatment programme (stable
MMT v. abstinence in former MMT patients). We
also tested for differences in cognitive impulsivity
and non-planning impulsivity comparing MMT, ABS
and healthy control groups. Stable MMT participants
deliberated longer and placed higher bets earlier on
the CGT and showed impaired strategic planning com-
pared with healthy controls. ABS participants showed
impairment in quality of decision-making, delay aver-
sion and risk adjustment on the CGT and non-
planning impulsivity compared with healthy controls.
MMT participants had widespread grey matter reduc-
tions in the orbitomedial prefrontal cortex, caudate,
putamen and globus pallidus. In contrast, ABS partici-
pants showed midbrain-thalamic grey matter reduc-
tions. The behavioural abnormalities correlate with
structural grey matter abnormalities, providing evi-
dence that the ABS group represent an intermediate
group, with regard to behavioural abnormalities and
brain structure abnormalities, between MMT partici-
pants and healthy controls.
Several studies have suggested impairment in cogni-
tive impulsivity and non-planning impulsivity in opi-
oid dependence (Ersche et al. 2005; Baldacchino et al.
2015). However, these studies did not address the
Fig. 2. Grey matter volume reductions. (a) Grey matter volume reductions in methadone maintenance treatment (MMT)
patients relative to controls. Regions are signiﬁcant (p < 0.01 whole-brain corrected level). (b) MMT patient (M), abstinent
patient (A) and healthy control (HC) subgroups within the prefrontal cortex (PFC) (Montreal Neurological Institute
coordinates −2, 34, 18). The central lines are medians; the boxes represent interquartile ranges; the whiskers represent ranges;
circles outliers; the asterisk is an extreme outlier. Median value of the MMT group was signiﬁcantly different (p < 0.01) from
those of the abstinent and control groups. (c) Grey matter volume reductions in abstinent patients relative to controls. Regions
are signiﬁcant (p < 0.01 whole-brain corrected level).
Table 3. Between-group comparisonsa
x y z z Value
Methadone group
Anterior cingulate −2 34 16 4.1
Orbitofrontal cortex 18 54 0 4.0
Caudate nucleus −18 12 12 4.6
Globus pallidus 10 10 2 3.3
Nucleus accumbens −6 10 10 4.1
Insula 34 −6 16 3.6
Occipital cortex 14 −98 −24 4.4
Abstinent group
Thalamus −2 −6 10 3.93
Midbrain 2 30 36 3.47
Grey matter reduction in methadone patients and abstin-
ent patients in comparison with controls. Coordinates (x, y,
z) reported in Montreal Neurological Institute space. All
results signiﬁcant at p < 0.01, cluster extent corrected across
the whole brain.
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issue of possible long-lasting changes as a result of
chronic opioid use, and not address the issue of pos-
sible reversibility with abstinence. Our ﬁndings pro-
vide evidence that cognitive processes that are
particularly associated with the prefrontal cortex are
disrupted during chronic opioid use, but not during
abstinence. MMT patients differed from healthy con-
trols in that they took longer to make decisions during
the CGT. However, the ABS group differed in delay
aversion outcomes for cognitive impulsivity. It is pos-
sible that these changes are related to opioid depend-
ence or the effects of subacute opioid withdrawal.
Our results show that MMT patients exhibited grey
matter reductions in the orbito-medial prefrontal cor-
tex, bilateral caudate nucleus and globus pallidus.
Notably, the orbito-medial prefrontal cortex is impli-
cated in processing drug-related information in addic-
tion (Volkow et al. 1997; Volkow & Fowler, 2000) and
the dorsal caudate in compulsive drug seeking and
habit formation (Everitt et al. 2008; Koob & Volkow,
2010). Abnormally reduced frontal cortex activity has
been linked with a reduction in dopamine striatal D2
receptor availability (Volkow et al. 1997). Consistent
with the latter, increased cognitive impulsivity
correlated with grey matter reductions in the orbito-
medial prefrontal cortex, but did not similarly correlate
in the ABS group. This suggests that orbitofrontal cor-
tex abnormalities are not linked to opioid exposure and
may, alternatively, be linked to vulnerability to de-
velop drug dependence (Adinoff et al. 2001), or an ef-
fect of non-opioid drug exposure prior to MMT
(Volkow et al. 2011). Consistent with the latter inter-
pretation, orbitofrontal grey matter reductions have
been reported to be associated with increased risk tak-
ing in cocaine-, amphetamine- and alcohol-dependent
individuals, using the Iowa Gambling Task (Tanabe
et al. 2009). In animal studies, there is evidence that
morphine administration increases impulsivity (Pattij
et al. 2009) which normalizes when administration is
stopped (Harvey-Lewis et al. 2012). In the present
study, a negative correlation between methadone
dose and CGT risk adjustment was present. This is
consistent with animal studies reporting pallidal
changes as a result of chronic opioid use (Gurwell
et al. 2001). As reported decades ago, bilateral gross
symmetric lesions of the globus pallidus were attribut-
able to heroin intoxication (Strassmann et al. 1969) and
subsequently more subtle lesions were observed in
Fig. 3. Grey matter volume and methadone maintenance treatment (MMT). (a) Grey matter reductions in the bilateral globus
pallidus in MMT patients correlating with stable methadone dose. (b) Grey matter reductions in the bilateral globus pallidus
in MMT patients correlating with Cambridge Gambling Task (CGT) risk adjustment scores. (c) Grey matter reductions in the
orbito-medial prefrontal cortex correlating with CGT risk-taking scores. (d) Grey matter volume reductions in the rostral
prefrontal cortex correlating with mean subsequent ﬁve moves from Stockings of Cambridge.
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Fig. 5. Summary. Brain abnormalities summarized according to the cortico-basal ganglia-thalamocortical loop. This circuit
originates from grey matter volume reductions in methadone maintenance treatment and abstinent patients signiﬁcantly
explained by opioid exposure (stable methadone dose, last stable methadone dose) and behavioural measures (Cambridge
Gambling Task and Stockings of Cambridge). GP, Globus pallidus.
Fig. 4. Grey matter volume and abstinent (ABS) patients. (a, b) Grey matter reductions in the bed nucleus of the stria
terminalis (BNST), thalamus (TH) and midbrain (MD) in ABS patients correlating with the last stable methadone dose. (c) No
grey matter reductions in the ABS group correlating with Cambridge Gambling Task risk taking. (d) Grey matter reductions
in the putamen and BNST in ABS patients correlating with mean subsequent ﬁve moves from Stockings of Cambridge.
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5–10% of heroin addicts at post-mortem (Andersen &
Skullerud, 1999). As with motor impairments as a con-
sequence of globus pallidus lesions (Andersen &
Skullerud, 1999), neuropsychological impairments
may depend on which part of the globus pallidus
that has been damaged. Furthermore, it has been
reported that hypoventilation caused by opioid use
with paradoxical vasoconstriction results in bilateral,
symmetrical infarcts of the globus pallidus (Daras
et al. 2001). Notably, sleep apnoea (Egan et al. 2005)
has been reported to occur in 30% of patients receiving
MMT (Wang & Teichtahl, 2007). The incidence of sleep
apnoea and ataxic breathing correlates with plasma
methadone levels (Wang et al. 2005) and opioid dose
(Walker et al. 2007). Consequently, there may be a
link between higher doses of methadone, sleep apnoea
and globus pallidus grey matter reductions. However,
it has been reported that changes observed in MRI may
be related to shifts in water content from and to glia
cells because of the effects of steroid hormones or cyto-
kines (Lucassen et al. 2014). This could be linked to
stress responses due to short-term abstinence (6
months) or as a result of methadone intake.
Abstinent patients exhibited grey matter reductions
in the thalamus and midbrain consistent with a previ-
ous study (Williams et al. 2007). Our study also found
grey matter reductions in the BNST associated with
increased LSMD. The BNST is a powerful modulator
of addictive behaviour, with a major input from nora-
drenergic innervation and is a dense centre of neurones
expressing corticotropin-releasing factor with cell bod-
ies and terminals which could also be linked with im-
pairment in cognitive impulsivity and non-planning
impulsivity (Koob & Volkow, 2010). The reduction in
the BNST may be speciﬁc to the abstinent group be-
cause it is involved in stress responses or it could be
associated with decreased stress in recovery. Deep
brain stimulation has been attempted previously in
the BNST in patients and there is some evidence for
drug dependence reduction (Langevin, 2012).
Consistent with this, we found that grey matter vol-
ume reductions in thalamus and midbrain grey matter
correlated negatively with measures of impaired cogni-
tive impulsivity and non-planning impulsivity.
In conclusion, as hypothesized, MMT maintained
patients exhibited abnormal behaviour linked to ab-
normal brain structure, and behavioural and brain ab-
normalities were least in ABS patients. However the
extent to which these differences reﬂect a coincidence
of MMT cessation or factors present during MMT pro-
moting cessation remain unclear. We therefore suggest
that a longitudinal study is required to determine
whether abstinence improves abnormalities, or
patients who achieve abstinence have reduced abnor-
malities before methadone cessation.
Table 4. Summary of the cognitive and neuroimaging outcomes
Cognitive domain Test Methadone group Abstinent group
Cognitive
impulsivity
CGT Quality of decision making, deliberation time,
risk adjustment
Quality of decision making, delay aversion, risk
adjustment
; Bilateral globus pallidus, ; orbito-medial
prefrontal cortex
; Periaqueductual grey, ; thalamus
Non-planning
impulsivity
SOC Problems solved in minimum moves, problems
solved in ﬁve moves, mean subsequent
thinking time ﬁve moves, mean subsequent
thinking time ﬁve moves
Problems solved in minimum moves, problems
solved in ﬁve moves, mean subsequent thinking
time ﬁve moves, mean subsequent thinking time
ﬁve moves
; Orbito-medial prefrontal cortex, ; putamen, ;
rostromedial prefrontal cortex
; Putamen, ; bed nucleus of stria terminalis
CGT, Cambridge Gambling Task; ;, reductions in grey matter; SOC, Stockings of Cambridge.
Table 5. Logistic regression modela
Predictor
EXP
(B) p
Frequency of use
Number of years dependent on heroin 0.04 0.024
Withdrawal exposure
Number of previous detoxiﬁcations
(opioid)
1.3 N.S.
Number of previous detoxiﬁcations
(alcohol)
2.5 N.S.
Treatment
Initial titration of methadone dose (index) 0.483 0.01
Stable methadone dose (mg) 0.483 0.002
Days receiving methadone treatment −0.511 0.03
N.S., Not signiﬁcant.
a Results of the binary logistic regression model with ex-
ponential (β) = EXP(B), using as the response at the treatment
outcome for the methadone group and abstinent group.
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